Welcome to our dedicated page for Ensign Group SEC filings (Ticker: ENSG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ensign Group, Inc. (ENSG) filings document its public-company reporting as a Delaware healthcare services company with common stock listed on the Nasdaq Global Select Market. Its disclosures cover skilled nursing and senior living operations, therapy and rehabilitative services, healthcare real estate, and the Standard Bearer real estate segment.
Ensign’s 8-K reports disclose quarterly and annual operating results and Regulation G non-GAAP measures, including adjusted net income, adjusted earnings per share, EBITDA, adjusted EBITDA, adjusted EBITDAR, adjusted EBT, and Funds from Operations for its real estate segment. Proxy materials cover shareholder voting, board governance, executive compensation, equity awards, capital-structure matters, and other governance disclosures.
The Ensign Group, Inc. (ENSG) filed a Form S-8 with the SEC on June 26, 2025 to register 4,230,804 additional shares of common stock (par $0.001) for issuance under its Amended and Restated 2022 Omnibus Incentive Plan. These shares are in addition to the 3,462,897 shares previously registered on October 26, 2022 (File No. 333-268018), bringing the total registration for the plan to roughly 7.7 million shares. The filing relies on General Instruction E of Form S-8 and incorporates by reference ENSG’s 2024 Form 10-K, its Q1-25 Form 10-Q, and three 2025 Form 8-Ks. Standard Delaware law indemnification provisions, exhibits (plan document, legal opinion, Deloitte consent, etc.), and Form S-8 undertakings are included. No financial results or new strategic transactions are disclosed; the document is strictly an administrative registration to cover future equity-based compensation grants.
Ensign Group (NASDAQ: ENSG) filed a Form 4 disclosing that Vice President & Chief Legal Officer Beverly B. Wittekind executed an option exercise and same-day sale on 18 June 2025 under a Rule 10b5-1 plan adopted 12 Sep 2024.
The officer exercised 4,719 employee stock options at an exercise price of $45.34, acquiring 4,719 common shares. All newly issued shares were immediately sold at $155.00 per share, generating gross proceeds of approximately $0.73 million.
After the sale, Wittekind’s direct ownership returned to 38,679 shares, unchanged in absolute terms but representing a disposal of roughly 11 % of her previously reported stake. No derivative securities remain outstanding from the exercised grant, which originally vested in five equal installments between 2020 and 2024.